News Sentiment

DXCM sentiment intelligence

DexCom Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 74.96 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

+5.2% over one week, -0.5% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

How Health Canada’s Longer-Wear CGM Approval At DexCom (DXCM) Has Changed Its Investment Story

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 5.2% Price confirming higher
Trend fit Trend active -0.5% over four weeks
Fair value -14.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
Ad Hoc News 6
MarketWatch 4
Stock Titan 4
simplywall.st 4
TradingView 3
Moomoo 2
StockStory 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 20
Regulatory and legal 4
Analyst action 3
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Simply Wall Street Direct company coverage

How Health Canada’s Longer-Wear CGM Approval At DexCom (DXCM) Has Changed Its Investment Story

Health Canada recently approved DexCom's G7 15 Day Continuous Glucose Monitoring System, extending sensor wear to 15.5 days with high accuracy. This approval is expected to reinforce DexCom's market position in Canada by enhancing convenience and digital health integration, thoug

Tone
Positive 64/100
Event
Regulatory and legal
Published
16 Jul 2026 00:43
Source
Simply Wall Street
MarketWatch Direct company coverage

DexCom Inc. stock underperforms Wednesday when compared to competitors

Shares of DexCom Inc. (DXCM) fell by 1.88% to $72.73 on Wednesday, despite a positive trading session for the broader stock market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. This marked the second consecutive day of losses for the company's stock.

Tone
Negative 29/100
Event
Market update
Published
15 Jul 2026 20:39
Source
MarketWatch
Stock Titan Direct company coverage

DXCM Company (NASDAQ: DXCM) shareholder to sell 1,700 shares

Michael Brown plans to sell 1,700 shares of DXCM common stock through Morgan Stanley Smith Barney LLC Executive Financial Services around July 15, 2026, valued at $126,514.00. This planned sale follows two previous sales by Brown of 1,700 shares each in May and June 2026. The sha

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:05
Source
Stock Titan
marketscreener.com Direct company coverage

Mizuho Adjusts Price Target on DexCom to $90 From $85, Maintains Outperform Rating

Mizuho analysts have increased their price target for DexCom (DXCM) to $90 from $85, while reiterating an Outperform rating on the stock. This adjustment reflects continued confidence in the medical equipment company, which specializes in continuous glucose monitoring systems. Th

Tone
Positive 72/100
Event
Analyst action
Published
15 Jul 2026 15:07
Source
marketscreener.com
MarketWatch Direct company coverage

DexCom Inc. stock outperforms competitors despite losses on the day

Shares of DexCom Inc. (DXCM) decreased by 2.92% to $74.12 on Tuesday, despite an overall positive trading session for the stock market, with the S&P 500 Index and Dow Jones Industrial Average both rising. This fall ended a two-day winning streak for the company's stock.

Tone
Negative 39/100
Event
Market update
Published
14 Jul 2026 21:07
Source
MarketWatch
The Globe and Mail Direct company coverage

DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM

DexCom (DXCM) has received Health Canada authorization for its Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for adults with diabetes, marking a significant regulatory milestone. This system offers real-time glucose readings for up to 15.5 days, aiming for simpler a

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 15:38
Source
The Globe and Mail
Investing.com Nigeria Direct company coverage

Dexcom receives Health Canada authorization for G7 15 Day CGM By Investing.com

Dexcom Inc. has received Health Canada authorization for its G7 15 Day Continuous Glucose Monitoring System for adults with diabetes. The system offers extended wear, waterproof sensors, and direct connectivity to Apple Watch, with additional features for tracking and sharing glu

Tone
Positive 71/100
Event
Market update
Published
14 Jul 2026 04:38
Source
Investing.com Nigeria
The Joplin Globe Direct company coverage

LE DEXCOM G7 15 JOURS A OBTENU L’AUTORISATION DE SANTÉ CANADA : UNE DURÉE DE PORT PROLONGÉE ET UNE CONTINUITÉ AMÉLIORÉE POUR LES ADULTES CANADIENS VIVANT AVEC LE DIABÈTE

Dexcom, Inc. has announced that Health Canada has authorized its Dexcom G7 15-day continuous glucose monitoring (CGM) system for adults aged 18 and over living with diabetes. This system offers the longest wear duration for a Health Canada-approved CGM and is designed for ease of

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 21:08
Source
The Joplin Globe
Investing.com Direct company coverage

Dexcom receives Health Canada authorization for G7 15 Day CGM

Dexcom Inc. has received Health Canada authorization for its G7 15 Day Continuous Glucose Monitoring System for adults with diabetes. The system offers real-time glucose readings, waterproof sensors, and direct connectivity features such as Apple Watch integration and Dexcom Clar

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 21:07
Source
Investing.com
Market source Direct company coverage

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Dexcom, Inc. has announced that Health Canada has authorized its Dexcom G7 15 Day Continuous Glucose Monitoring System for Canadian adults with diabetes. This system offers the longest wear time and highest accuracy among Health Canada-authorized CGM systems, providing real-time

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 21:07
Source
Market source
MarketWatch Direct company coverage

DexCom Inc. stock outperforms competitors on strong trading day

DexCom Inc. (DXCM) saw its stock rise by 1.85% to $76.35 on Monday, outperforming the broader market as both the S&P 500 Index and Dow Jones Industrial Average fell. This marks the second consecutive day of gains for the company's stock despite a weak trading session.

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 21:07
Source
MarketWatch
The Facts Direct company coverage

DEXCOM,-INC.

Dexcom G7 15 Day has received authorization from Health Canada. The continuous glucose monitoring system is compatible with smart devices, which are sold separately. Further compatibility information is available on Dexcom's website.

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 20:46
Source
The Facts
StreetInsider Direct company coverage

Guarantor: JPMorgan Chase & Co.

This document is a pricing supplement for structured investments offered by JPMorgan Chase Financial Company LLC, guaranteed by JPMorgan Chase & Co. These auto callable contingent interest notes are linked to the common stock of DexCom, Inc. and are designed for investors seeking

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:08
Source
StreetInsider
MarketWatch Direct company coverage

DexCom Inc. stock underperforms Thursday when compared to competitors

Shares of DexCom Inc. (DXCM) fell by 1.40% to $73.02 on Thursday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average rise. This decline ended a five-day winning streak for DexCom stock.

Tone
Negative 40/100
Event
Market update
Published
09 Jul 2026 20:57
Source
MarketWatch
Sahm Direct company coverage

Is DexCom’s (DXCM) Sensor Recall Exposing Deeper Questions About Its Quality Controls and Data Systems?

DexCom (DXCM) has initiated a voluntary Class II recall of specific G7 continuous glucose monitoring sensor lots due to theft during destruction, leading to improper sterilization and potential inaccuracies. This incident, combined with previous app-related recalls, raises concer

Tone
Negative 29/100
Event
Regulatory and legal
Published
09 Jul 2026 17:07
Source
Sahm
Business Wire Direct company coverage

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) announced it will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss its performance. Details for acce

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 12:31
Source
Business Wire
Ad-hoc-news.de Direct company coverage

Dexcom Inc. focuses on continuous glucose monitoring as investors track long-term growth

Dexcom Inc. specializes in continuous glucose monitoring (CGM) systems for diabetes management, a key area for growth investors. The company's Nasdaq listing and focus on recurring revenue from sensor sales position it well in the expanding diabetes care market. Dexcom's G6 and G

Tone
Positive 76/100
Event
Earnings
Published
09 Jul 2026 10:07
Source
Ad-hoc-news.de